Are platforms the new products? That was the question posed during a BIO-Europe Spring panel discussion with industry leaders from prominent platform companies operating across the spectrum of life sciences. These included the scientific and therapeutic expertise at Evotec SE, the proteomics know-how of SomaLogic, Inc., to the emerging field of AI-enabled drug discovery in which Insilico Medicine operates.
Juicy Apples Come From Healthy Trees: Advice For Platform Developers
Speaking at BIO-Europe Spring, three leaders of platform life sciences companies offer advice on their scalable and lower risk business models that support innovation within partner biopharma companies.
More from Innovation
More from In Vivo
• By
Despite the significant presence of East Asian professionals in the pharmaceutical industry, their representation in top leadership roles remains disproportionately low. This disparity can be attributed to cultural bias, limited access to influential networks, and systemic barriers within corporate structures.
• By
The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.
• By
Farideh Bischoff, chief medical officer of Heranova Lifesciences, discusses the urgent need for better diagnostic options and the latest innovations transforming care for endometriosis patients.